|
Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2 Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2 conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2 Clinical research trials and Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2 medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2. Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2 Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2 clinical trial. Participants frequently get the best healthcare available for their Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2 condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2  Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2
Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2
For Condition: HIV Infections
Status: Completed
Sponsor(s): Rockefeller University ,
Synopsis: To evaluate the safety and immunological effects of polyethylene glycolated-interleukin-2 (PEG-IL-2) on asymptomatic (without symptoms) HIV-seropositive patients who are taking zidovudine (AZT). To enhance measures of immune function with well-tolerated doses of PEG-IL-2, an immunomodulator, in a regimen designed to allow its use in outpatients with normal daily activity (i.e., full-time employment, etc.). Recombinant IL-2 (without PEG modification) was administered to HIV-infected patients by daily intradermal injection. At the low doses used, this was non-toxic, well-tolerated, and gave a systemic response as measured by natural killer cell and lymphokine-activated killer cell activity, but required daily administration. In the current study, the PEG modification of IL-2 is used since it has a much longer prolonged half-life compared with the non-PEG compound, without loss of functional activity.
Details: Recombinant IL-2 (without PEG modification) was administered to HIV-infected patients by daily intradermal injection. At the low doses used, this was non-toxic, well-tolerated, and gave a systemic response as measured by natural killer cell and lymphokine-activated killer cell activity, but required daily administration. In the current study, the PEG modification of IL-2 is used since it has a much longer prolonged half-life compared with the non-PEG compound, without loss of functional activity. In the first, dose-escalation phase of the study, PEG-IL-2 is injected into the skin of the back by either the intradermal (ID) or subcutaneous (SC) route, to establish an optimal dose (which when given ID results in local induration = or > 25 mm without significant toxicity). The ID and SC routes are compared for systemic effect and toxicity. In the second phase of the study, the PEG-IL-2 is administered for 6-8 weeks using the optimal dosage, frequency, and route determined in the initial phase (probably 2-3 times per week) while local and systemic effects are monitored. These include measures of viral titer, peripheral blood mononuclear cell phenotype, CBC and CD4 counts, and in vitro cytotoxicity assays.
Eligibility:
Study Type: Interventional, Treatment, Dose Comparison
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Zidovudine (AZT). - Necessary topical agents such as nystatin, clotrimazole, and acyclovir. - Aerosolized pentamidine for Pneumocystis carinii pneumonia (PCP) prophylaxis. - Oral antibiotics for PCP prophylaxis if hematologically stable for = or > 30 days prior to study entry. - Necessary systemic agents for the treatment of other chronic disorders, such as diabetes or asthma. Patients must have: - HIV-1 seropositivity. - Asymptomatic. - No opportunistic infection for 8 weeks prior to study entry. - Been on azidothymidine (AZT) (= or > 500 mg/day) for at least 8 weeks prior to beginning interleukin-2 (IL-2), with stable CD4 cell counts. Prior Medication: Allowed: - Zidovudine (AZT). Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Active, life-threatening opportunistic infection (OI) with bacterial, viral, fungal, or protozoan pathogens. - Fever = or > 101 F. within 10 days prior to study entry. - Significant central nervous system (CNS) disease including AIDS dementia, psychiatric disability, or seizure disorder. - Significant cardiac disease (New York Heart Association Stage III or IV). - Significant pulmonary disease (Forced Expiratory Volume < 75 percent. - Weight loss = or > 10 percent within last 3 months. Concurrent Medication: Excluded: - Systemic therapy for opportunistic infection (OI). Patients with the following are excluded: - Presence of antibody to interleukin-2 (IL-2). - Diseases or symptoms listed in Exclusion Co-Existing Conditions. Prior Medication: Excluded within 12 weeks prior to study entry: - Other immunomodulators. - Corticosteroids. - Other experimental therapy. - Anti-neoplastic chemotherapy. Active drug or alcohol abuse.
Total Enrollment:
Location and Contact Information:
Rockefeller Univ
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: 072A; COH-010-0790
Study Start Date:
Record last reviewed: August 1991
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002017
Other Hiv Infections Studies:
1. A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis
2. A Study of Dideoxycytidine in HIV-Infected Patients
3. Effect of a T-20 Based Anti-HIV Drug Regimen on HIV Reservoirs
4. ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past
5. A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3
Related Studies:
Other HIV Infections Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2
|
|
|
|
|
|
|
|
